Compare Natera Inc. Common Stock (NTRA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Materials Select Sector SPDR Fund trades at $50 (market cap $7.91B). The key difference: Natera Inc. Common Stock is far larger — about 7.2× Materials Select Sector SPDR Fund's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Materials Select Sector SPDR Fund for 71 Days on average.
| NTRA | XLB | |
|---|---|---|
Market Cap | $57.03B | $7.91B |
Volume | 1,131,157 | 8,895,844 |
Sector | Health | — |
52-Week High | $425.64 | $53.67 |
52-Week Low | $179.42 | $42.23 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
XLB trades at $49.72 with a modest 0.57% daily gain, though technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent news highlights both challenges from September's sector volatility and opportunities from infrastructure spending and AI-related demand.
The outlook remains cautious given technical weakness and sector cyclicality. While long-term infrastructure trends provide support, current valuations appear stretched with limited near-term catalysts. Key risks include China supply chain dependencies and economic sensitivity, requiring careful position sizing for materials exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
